Industry top-down
Medical Devices
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
The median revenue growth rate for covered companies in the medical device sector reached 8.47% YoY, with many firms sustaining top-line expansion. However, on the bottom line, there was a pronounced polarization in profitability: while select companies such as Stryker posted EPS growth exceeding 40%, others like Abbott and Edwards experienced negative growth. In addition, certain research- and component-related companies, including 10x Genomics, saw their revenues contract.
- Median revenue growth at 8.5%, with many companies sustaining top-line growth
- Multiple companies post double-digit revenue growth (MDT, DXCM, etc.)
- Select names show significant EPS improvement of 30–44%
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| ABTABBOTT LABORATORIES | FY2026 Q3 | $13.01B | +14.5% | $0.53 | -43.6% | — |
| MDTMedtronic plc | FY2027 Q1 | $9.76B | +13.7% | $1.14 | +40.7% | — |
| SYKSTRYKER CORP | FY2026 Q3 | $6.52B | +7.6% | $1.96 | -11.7% | — |
| BSXBOSTON SCIENTIFIC CORP | FY2026 Q3 | $5.14B | +1.4% | $0.40 | -21.6% | — |
| EWEdwards Lifesciences Corp | FY2026 Q3 | $1.72B | +10.5% | $0.53 | +6.0% | — |
| GEHCGE HealthCare Technologies Inc. | FY2026 Q3 | $5.51B | +7.2% | $1.36 | +38.8% | — |
| DXCMDEXCOM INC | FY2026 Q3 | $1.34B | +11.2% | $0.72 | +2.9% | — |
| STESTERIS plc | FY2026 Q3 | $1.5B | +9.2% | $1.96 | +12.0% | — |
| ZBHZIMMER BIOMET HOLDINGS, INC. | FY2026 Q3 | $2.06B | +3.1% | $1.00 | -13.8% | — |
| GKOSGLAUKOS Corp | FY2026 Q3 | $211.03M | +58.0% | $0.03 | — | — |
| PENPenumbra Inc | FY2026 Q3 | $410.15M | +15.6% | $1.07 | -8.5% | — |
| BIO-BBIO-RAD LABORATORIES, INC. | FY2026 Q3 | $656.4M | +0.5% | $17.02 | — | — |
| BIOBIO-RAD LABORATORIES, INC. | FY2026 Q3 | $656.4M | +0.5% | $17.02 | — | — |
| PODDINSULET CORP | FY2026 Q3 | $842M | +19.2% | $2.03 | +63.7% | — |
| GMEDGLOBUS MEDICAL INC | FY2026 Q3 | $763.72M | -0.7% | $1.04 | +18.2% | — |
| BRKRBRUKER CORP | FY2026 Q3 | $874M | +1.6% | $-0.81 | — | — |
| MASIMASIMO CORP | FY2026 Q1 | $372M | +9.5% | $-3.12 | — | — |
| TXG10x Genomics, Inc. | FY2026 Q3 | $150.67M | +1.1% | $-0.15 | — | — |
| HAEHAEMONETICS CORP | FY2027 Q2 | $357.76M | +9.3% | $1.00 | +23.5% | — |
| LIVNLivaNova PLC | FY2026 Q3 | $393.15M | +9.9% | $0.11 | -77.6% | — |
| ITGRInteger Holdings Corp | FY2026 Q3 | $449.66M | -3.9% | $0.43 | -61.3% | — |
| AXGNAxogen, Inc. | FY2026 Q3 | $75.83M | +26.2% | $0.04 | +300.0% | — |
| TMDXTransMedics Group, Inc. | FY2026 Q3 | $203.01M | +41.1% | $0.46 | -30.3% | — |
| IRTCiRhythm Holdings, Inc. | FY2026 Q3 | $221.59M | +14.9% | $-0.90 | — | — |
| NEOGNEOGEN CORP | FY2027 Q1 | $222.8M | +6.5% | $-0.05 | — | — |
| UFPTUFP TECHNOLOGIES INC | FY2026 Q3 | $172.43M | +11.6% | $2.64 | +25.1% | — |
| ALMRAlamar Biosciences, Inc. | FY2026 Q3 | $33.55M | — | $-0.19 | — | — |
| ESTAESTABLISHMENT LABS HOLDINGS INC. | FY2026 Q3 | $71.99M | +33.9% | $-0.35 | — | — |
| BFLYButterfly Network, Inc. | FY2026 Q3 | $32.6M | +51.7% | $-0.05 | — | — |
| INSPInspire Medical Systems, Inc. | FY2026 Q3 | $206.7M | -7.9% | $-0.84 | — | — |
| ENOVEnovis CORP | FY2026 Q3 | $558.73M | +1.8% | $0.06 | — | — |
| LMRILumexa Imaging Holdings, Inc. | FY2026 Q2 | $264.16M | — | $0.03 | — | — |
| CNMDCONMED Corp | FY2026 Q3 | $335.56M | -0.7% | $0.66 | — | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).